ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program
Sep 03, 2026
Gurugram (Haryana)/ New Delhi [India], September 3: ZoeNCure Therapeutics Pvt. Ltd., an oncology biotechnology company focused on developing high-potency targeted cancer therapies, today announced the successful closing of an INR 20 Crore (approx. $2.4 Million USD) Seed financing round. The investment was led by the HNI (High-Net-Worth Individual) Tyagi Family based out of Gurugram, India, led by Mr. Shyambir Tyagi and Manoj Tyagi, alongside participating angel co-investors.
Read More...
